BR112016002001B1 - Uso de anticorpo monoclonal, método in vitro para detectar células b ativadas, reagente para detectar células b ativadas, método in vitro para suprimir a atividade b das células ativadas, e anticorpo monoclonal - Google Patents

Uso de anticorpo monoclonal, método in vitro para detectar células b ativadas, reagente para detectar células b ativadas, método in vitro para suprimir a atividade b das células ativadas, e anticorpo monoclonal Download PDF

Info

Publication number
BR112016002001B1
BR112016002001B1 BR112016002001-4A BR112016002001A BR112016002001B1 BR 112016002001 B1 BR112016002001 B1 BR 112016002001B1 BR 112016002001 A BR112016002001 A BR 112016002001A BR 112016002001 B1 BR112016002001 B1 BR 112016002001B1
Authority
BR
Brazil
Prior art keywords
seq
variable region
antibody
light chain
heavy chain
Prior art date
Application number
BR112016002001-4A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112016002001A2 (pt
Inventor
Tomohide Yamazaki
Mayuki Endo
Koji Ishida
Original Assignee
SBI Biotech Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SBI Biotech Co., Ltd filed Critical SBI Biotech Co., Ltd
Publication of BR112016002001A2 publication Critical patent/BR112016002001A2/pt
Publication of BR112016002001B1 publication Critical patent/BR112016002001B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
BR112016002001-4A 2013-07-30 2014-07-30 Uso de anticorpo monoclonal, método in vitro para detectar células b ativadas, reagente para detectar células b ativadas, método in vitro para suprimir a atividade b das células ativadas, e anticorpo monoclonal BR112016002001B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013-158258 2013-07-30
JP2013158258 2013-07-30
PCT/JP2014/070661 WO2015016386A1 (en) 2013-07-30 2014-07-30 Medicament comprising anti-phospholipase d4 antibody

Publications (2)

Publication Number Publication Date
BR112016002001A2 BR112016002001A2 (pt) 2017-08-29
BR112016002001B1 true BR112016002001B1 (pt) 2023-04-25

Family

ID=51493000

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016002001-4A BR112016002001B1 (pt) 2013-07-30 2014-07-30 Uso de anticorpo monoclonal, método in vitro para detectar células b ativadas, reagente para detectar células b ativadas, método in vitro para suprimir a atividade b das células ativadas, e anticorpo monoclonal

Country Status (17)

Country Link
US (2) US20160168266A1 (https=)
EP (1) EP3027656B1 (https=)
JP (3) JP6431523B2 (https=)
KR (1) KR102367760B1 (https=)
CN (1) CN105745226B (https=)
AU (1) AU2014297217B2 (https=)
BR (1) BR112016002001B1 (https=)
CA (1) CA2919736C (https=)
DK (1) DK3027656T3 (https=)
ES (1) ES2736324T3 (https=)
HU (1) HUE044469T2 (https=)
MX (1) MX381725B (https=)
PL (1) PL3027656T3 (https=)
RU (1) RU2709741C2 (https=)
SG (2) SG10201800592SA (https=)
TR (1) TR201910330T4 (https=)
WO (1) WO2015016386A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
EP3431504B1 (en) * 2012-01-31 2021-03-24 SBI Biotech Co., Ltd. Anti-phospholipase d4 antibody
MX381725B (es) * 2013-07-30 2025-03-13 Sbi Biotech Co Ltd Medicamento que comprende anticuerpo anti-fosfolipasa d4.
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
KR20210006321A (ko) 2018-01-12 2021-01-18 다케다 야쿠힌 고교 가부시키가이샤 항-cd38 항체의 피하 투여
JP7140367B2 (ja) * 2018-05-31 2022-09-21 国立大学法人 東京大学 ヒト由来サンプルにおける可溶型ｔｌｒ７の分析

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD1367C2 (ro) * 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
AU5784799A (en) * 1998-08-24 2000-03-14 Alphagene, Inc. Secreted proteins and polynucleotides encoding them
US20020146686A1 (en) * 2000-12-07 2002-10-10 Millennium Pharmaceuticals, Inc. Methods and compositions for the diagnosis and treatment of viral disease using 55092
JP2013052781A (ja) 2011-09-05 2013-03-21 Tokai Rika Co Ltd 車両用ミラー装置
EP3431504B1 (en) * 2012-01-31 2021-03-24 SBI Biotech Co., Ltd. Anti-phospholipase d4 antibody
MX381725B (es) * 2013-07-30 2025-03-13 Sbi Biotech Co Ltd Medicamento que comprende anticuerpo anti-fosfolipasa d4.

Also Published As

Publication number Publication date
DK3027656T3 (da) 2019-08-05
CN105745226B (zh) 2020-03-06
CN105745226A (zh) 2016-07-06
EP3027656B1 (en) 2019-06-26
RU2016106708A (ru) 2017-09-01
US20210130493A1 (en) 2021-05-06
JP2019214621A (ja) 2019-12-19
JP2016534022A (ja) 2016-11-04
AU2014297217B2 (en) 2020-01-16
MX2016001193A (es) 2016-05-26
SG10201800592SA (en) 2018-03-28
EP3027656A1 (en) 2016-06-08
KR102367760B1 (ko) 2022-02-24
AU2014297217A1 (en) 2016-02-18
RU2016106708A3 (https=) 2018-03-30
SG11201600666SA (en) 2016-02-26
JP6431523B2 (ja) 2018-11-28
ES2736324T3 (es) 2019-12-27
JP6843449B2 (ja) 2021-03-17
WO2015016386A1 (en) 2015-02-05
JP2019014759A (ja) 2019-01-31
CA2919736A1 (en) 2015-02-05
KR20160034934A (ko) 2016-03-30
MX381725B (es) 2025-03-13
RU2709741C2 (ru) 2019-12-19
US20160168266A1 (en) 2016-06-16
HUE044469T2 (hu) 2019-10-28
PL3027656T3 (pl) 2019-10-31
BR112016002001A2 (pt) 2017-08-29
TR201910330T4 (tr) 2019-07-22
CA2919736C (en) 2022-03-22

Similar Documents

Publication Publication Date Title
US20210130493A1 (en) Medicament comprising anti-phospholipase d4 antibody
JP7244102B2 (ja) 抗ホスホリパーゼｄ４抗体
JP2022529350A (ja) アンタゴニスト抗ｃｄ７抗体
CA3099176A1 (en) Anti-sirp-beta1 antibodies and methods of use thereof
WO2019204756A1 (en) Anti-cd40 antibodies and uses thereof
BR112014018539B1 (pt) Método de preparar um hibridoma que produz um anticorpo monoclonal, hibridoma, anticorpo monoclonal ou um fragmento contendo uma região de ligação ao antígeno do mesmo, método de preparar um anticorpo monoclonal, método ex vivo de detectar uma célula dendrítica plasmacitóide, reagente para a detecção de uma célula dendrítica plasmacitóide, método ex vivo de suprimir uma atividade de uma célula dendrítica plasmacitóide e agente para suprimir uma atividade de uma célula dendrítica plasmacitóide

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/07/2014, OBSERVADAS AS CONDICOES LEGAIS